Pharmac Updates 16/10/2026
Please see below updates from Pharmac.
Supply issue
Medsafe approval, Teriparatide Teva Inj 250 mcg per ml, 2.4 ml
Brand change
Cetirizine hydrochloride oral liquid 1mg/ml
1.Supply Issue update: Medsafe approval, Teriparatide Teva Inj 250 mcg per ml, 2.4 ml
An alternate product was funded from August - Teriparatide S29 20 micrograms/80 microlitres, solution for Injection Pre-filled Pen 2.4 ml
This UK-branded teriparatide has now received approval from Medsafe. It can be prescribed and dispensed as normal from now. The Section 29 label will be removed from the Schedule when it is updated for November 2026. Teriparatide on Pharmac website
1.Brand change: cetirizine hydrochloride oral liquid 1mg/ml
Cetirizine Hayfever & Allergy Relief (Noumed) will be listed (funded) from 1 November 2026.
This will be the funded brand going forward and has Principal Supply Status (PSS) from 1 April 2027 to 30 June 2029 in the community and in Health New Zealand hospitals.
Cetirizine Hayfever & Allergy Relief will come in a 200 ml plastic bottle and include a measuring cup attached to the cap to support safer and more accurate administration.
Like Histaclear oral liquid 1mg/ml, Cetirizine Hayfever & Allergy Relief is banana flavoured and is considered gluten, lactose, sugar and alcohol free because their presence is negligible and is approved by Medsafe.
Histaclear will be delisted (no longer funded) from the Pharmaceutical Schedule on 1 April 2027.
Ngā mihi,
Pharmac Implementation Team
Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
P: 0800 660 050 | www.pharmac.govt.nz
